New farnesyltransferase inhibitors in the phenothiazine series

被引：39
作者：
Belei, Dalila [1 ]
Dumea, Carmen [1 ]
Samson, Alexandrina [1 ]
Farce, Amaury [2 ,3 ]
Dubois, Joelle [4 ]
Bicu, Elena [1 ]
Ghinet, Alina [1 ,2 ,5 ]
机构：
[1] Alexandru Ioan Cuza Univ, Fac Chem, Dept Organ Chem, Iasi 700506, Romania
[2] Univ Lille Nord France, F-59000 Lille, France
[3] Inst Chim Pharmaceut Albert Lespagnol, EA GRIIOT, IFR114, F-59006 Lille, France
[4] Ctr Rech Gif, CNRS, Inst Chim Subst Nat, UPR2301, F-91198 Gif Sur Yvette, France
[5] UCLille, GRIIOT, Lab Pharmacochim, EA 4481, F-59046 Lille, France
来源：
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2012年 / 22卷 / 14期
关键词：
Farnesyltransferase inhibitor; Anticancer agent; Phenothiazine; Triazole; FARNESYL TRANSFERASE INHIBITORS; PROTEIN FARNESYLTRANSFERASE; RAS GENES; N-RAS; CANCER; ASSAY; CARCINOMAS; BMS-214662; PANCREAS; AGENTS;
D O I：
10.1016/j.bmcl.2012.06.007
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
The biological screening of the chemical library of our Organic Chemistry Department, carried out on an automated fluorescence-based FTase assay, allowed us to discover that a phenothiazine derivative (1d) was an inhibitor of farnesyltransferase. Three new series of human farnesyltransferase inhibitors, based on a phenothiazine scaffold, were synthesized with protein farnesyltransferase inhibition potencies in the low micromolar range. Ester derivative 9d was the most active compound in these series. Four synthesized compounds were evaluated for their antiproliferative activity on a NCI-60 cancer cell line panel. The modest results obtained in this preliminary investigation showed that mixing the phenothiazine and the 1,2,3-triazole motif in the structure of a single compound can lead to new scaffolds in the field of farnesyltransferase inhibitors. (C) 2012 Elsevier Ltd. All rights reserved.
引用
收藏
页码：4517 / 4522
页数：6
相关论文
共 47 条
  • [1] MOST HUMAN CARCINOMAS OF THE EXOCRINE PANCREAS CONTAIN MUTANT C-K-RAS GENES
    ALMOGUERA, C
    SHIBATA, D
    FORRESTER, K
    MARTIN, J
    ARNHEIM, N
    PERUCHO, M
    [J]. CELL, 1988, 53 (04) : 549 - 554
  • [2] Frequency of RAS gene mutation and its cooperative genetic events in Southeast Asian adult acute myeloid leukemia
    Auewarakul, Chirayu U.
    Lauhakirti, Darat
    Tocharoentanaphol, Chintana
    [J]. EUROPEAN JOURNAL OF HAEMATOLOGY, 2006, 77 (01) : 51 - 56
  • [3] Belei D., 2009, Acta Chem. Ias, V17, P197
  • [4] A Selective Synthesis of Enamines versus Aziridines
    Belei, Dalila
    Bicu, Elena
    Jones, Peter G.
    Birsa, M. Lucian
    [J]. JOURNAL OF HETEROCYCLIC CHEMISTRY, 2011, 48 (01) : 129 - 134
  • [5] Inhibitors of farnesyltransferase: A rational approach to cancer chemotherapy?
    Bell, IM
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2004, 47 (08) : 1869 - 1878
  • [6] 3-aminopyrrolidinone farnesyltransferase inhibitors: Design of macrocyclic compounds with improved pharmacokinetics and excellent cell potency
    Bell, IM
    Gallicchio, SN
    Abrams, M
    Beese, LS
    Beshore, DC
    Bhimnathwala, H
    Bogusky, MJ
    Buser, CA
    Culberson, JC
    Davide, J
    Ellis-Hutchings, M
    Fernandes, C
    Gibbs, JB
    Graham, SL
    Hamilton, KA
    Hartman, GD
    Heimbrook, DC
    Homnick, CF
    Huber, HE
    Huff, JR
    Kassahun, K
    Koblan, KS
    Kohl, NE
    Lobell, RB
    Lynch, JJ
    Robinson, R
    Rodrigues, AD
    Taylor, JS
    Walsh, ES
    Williams, TM
    Zartman, CB
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2002, 45 (12) : 2388 - 2409
  • [7] BOS JL, 1989, CANCER RES, V49, P4682
  • [8] Activation of RAS Family Genes in Urothelial Carcinoma
    Boulalas, I.
    Zaravinos, A.
    Karyotis, I.
    Delakas, D.
    Spandidos, D. A.
    [J]. JOURNAL OF UROLOGY, 2009, 181 (05) : 2312 - 2319
  • [9] Boyd R. B., 1997, ANTICANCER DRUG DEV, P23
  • [10] Caponigro F, 2003, EXPERT OPIN INV DRUG, V12, P943, DOI 10.1517/eoid.12.6.943.21785
12345